News | Endovascular Aortic Repair | January 31, 2020

New Reporting Standards for Type B Aortic Dissections

STS and SVS release new TBAD reporting standards that consolidate nomenclature and terminology 

Thoracic abdominal aortic stent graft used to treat  Type B aortic dissections (TBAD). The STS and SVS released new reporting standards for TBAD.

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting standards to ensure patients with Type B aortic dissections (TBAD) receive appropriate treatment and care.

The care of patients with Type B dissections has evolved over time and now includes medical, surgical and endovascular therapies. Therapy is often in a multidisciplinary environment, and performed by several specialties, including vascular surgery, cardiothoracic surgery, interventional radiology and cardiology.

However, TBAD remains a life-threatening problem whose treatment has been confused by differences in nomenclature and terminology. This combined effort by the SVS and STS provides a unified consensus on reporting, nomenclature and classification of TBAD. The revision was led by Joseph Lombardi, M.D., head, division of vascular and endovascular surgery, Cooper University Healthcare, of SVS, and Chad Hughes, M.D., associate professor of surgery, Duke University, of STS.

“The new reporting standards represent the culmination of more than a year’s long effort by a writing team consisting of subject matter experts from the SVS and STS,” Hughes said. “The multidisciplinary input from both vascular and cardiothoracic surgeons is unique and has resulted in a document that will define proper reporting for this complex topic. Uniform reporting will allow standardized comparisons across series between different institutions worldwide with the goal being data that will best inform outcomes and guide best practices going forward.”

Acute aortic dissection is the most common emergency affecting the aorta, with high mortality and morbidity rates without appropriate and timely care. “With the recent blanket U.S. Federal Drug Administration (FDA) approval of endovascular stent grafting for type B aortic dissection, as well as our maturing understanding of the anatomy and pathophysiology of the disease, there has been an explosion of literature in multiple specialty journals regarding TBAD presentation, treatment and outcomes,” Lombardi said. “The purpose of this document is to provide structure to the reporting of TBAD, with particular attention to those attributes of TBAD which, based on the best available evidence to date, would appear to impact outcomes.”

The SVS/STS Reporting Standards introduce a new classification system with several new and easy-to-use features created by combining previous classification systems with the well-known anatomic zones of the aorta. “The new classification system provides an easy way to be descriptive of patients’ anatomy using language that is relevant to the way we currently treat patients,” Lombardi explained.

Another important area described is the need for a clear and consistent definition of chronicity of aortic dissections. The new standards also provide definitions of “uncomplicated” and “complicated” dissections and includes a new “high-risk” category of dissections that is defined by the presence of specific ominous clinical and radiographic features when a patient presents with a TBAD. These reporting standards also provide strict definitions of the common clinical complications of dissections and how they should be described and reported.

“The document addresses a number of limitations of the current literature by bringing consistency to all aspects of type B dissection reporting such as definitions of dissection chronicity, complicated versus uncomplicated versus high-risk dissection status, classification of dissections involving the aortic arch, which are not well described using the current Stanford and DeBakey systems, as well as a uniform definition of ‘aortic remodeling,’ among others,” Hughes said.

These are just some of the new features that will make these SVS/STS Reporting Standards an essential tool by providing a common language around dissections for clinicians, investigators, industry partners and regulatory agencies, SVS and STS representatives said.   

Read the new guideline: www.jvascsurg.org/article/S0741-5214(19)32649-7/fulltext

Aortic Dissection: Management and Treatment

 

 

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major